(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 May 2007 (18.05.2007)

PCT

(10) International Publication Number
WO 2007/054809 A3

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 5/24* (2006.01)

(21) International Application Number:
PCT/IB2006/003181

(22) International Filing Date:
2 November 2006 (02.11.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/736,623 14 November 2005 (14.11.2005) US

(71) Applicant *(for all designated States except US)*: **RINAT NEUROSCIENCE CORP.** [US/US]; 230 E. Grand Avenue, South San Francisco, California 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ZELLER, Joerg** [DE/US]; Rinat Neuroscience Corp., 230 East Grand Avenue, South San Francisco, California 94080 (US). **POULSEN, Kristian, Todd** [US/US]; Rinat Neuroscience Corp., 230 East Grand Avenue, South San Francisco, California 94080 (US). **ABDICHE, Yasmina, Noubia** [GB/US]; Rinat Neuroscience Corp., 230 East Grand Avenue, South San Francisco, California 94080 (US). **PONS, Jaume** [ES/US]; Rinat Neuroscience Corp., 230 East Grand Avenue, South San Francisco, California 94080 (US). **COLLIER, Sierra, Jones** [US/US]; Rinat Neuroscience Corp., 230 East Grand Avenue, South San Francisco, California 94080 (US). **ROSENTHAL, Arnon** [US/US]; 150 Normandy Lane, Woodside, California 94062 (US).

(74) Agent: **FULLER, Grover, F., Jr.**; Pfizer Inc., 150 East 42nd Street, New York, NY 10017-5612 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
9 August 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME

Fab	K_D (nM) 1-37 (WT)	K_D (nM) 19-37[a]	K_D (nM) 25-37[a]	K_D (mutant/parent) F27A	V28A	P29A	T30A	N31A	V32A	G33A	S34A	K35A	F37A
7E9	1.0	1.1±0.8	*0.14±0.05*	1.0	1.0	26	7	9	41	1256	69	4	3598
8B6	1.1	1.5±1.2	*0.45±0.08*	1.0	1.0	9	2.2	3	5	496	26	3	2527
10A8	2.1	2.4±1.4	*1.0±0.2*	1.0	1.0	9	4	4	11	36	82	13	2152
7D11	4.4	10±7	*3.4±0.4*	1.1	1.0	7	4	5	5	86	18	1.4	420
6H2	9.3	7.8±0.2	*8.5±0.5*	0.9	1.0	1.0	0.8	4	11	14	0.5	1.0	
4901	60.5	52±12	*296±115*	0.8	0.8	0.2	0.2	0.3	0.9	1.3	0.8	0.3	
14E10	79.7	91±3	*117.4±0.7*	0.8	0.8	11	3	18	2	1	3	0.4[b]	
9B8	84.7	76±20	*96±28*	0.8	0.8	0.6	0.6	0.7	0.6	1.3	4	0.4[b]	
13C2	94.4	86±13	*137±5*	0.7	0.7	0.5	0.4	0.6	0.2	0.9	1.1	0.4[b]	
14A9	148.4	219±114	*246±20*	0.8	0.7	0.7	0.5	0.8	0.7	1.6	1.3	6	
6D5	209.9	207±26	*378±22*	0.8	0.7	0.5	0.4	0.6	0.5	3	1.1	5	
1C5	296.4	223±51	*430±173*	0.8	0.8	0.6	0.4	0.6	0.6	1.1	1.1	5	

(57) Abstract: The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

WO 2007/054809 A3